Dr Sheuli Porkess of the ABPI applauds the Sector Deal 2 for helping to boost opportunities for patients to engage in research, but says there’s more to do.
Julian Sturdy MP, Chair of the All-Party Parliamentary Group on Antibiotics, explains why AMR should remain a key issue for the Government.
On World Antibiotic Awareness Day, Public Affairs Manager Harriet Adams gives some key facts which illustrate the need to act now to address the challenge of antibiotic resistance.
Professor Carole Longson, Chief Scientific Officer at the Association of the British Pharmaceutical Industry gives her nominations for a woman in science to go on the £50 note.
This year the Nobel Prize Committee has awarded the Physiology or Medicine prize to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. This week we're highlighting four other discoveries over the past 100 years that have changed the...
Antibiotic resistance has always been a global public health problem. While many of my colleagues carry out research aimed at discovering new antibiotics, my job is to help all of us get better at looking after the antibiotics we already have.
In a week that sees the MHRA and CRUK publish critical information about the UK’s clinical research environment post-Brexit, ABPI's Deputy Chief Scientific Officer Dr Sheuli Porkess explores what it means for the pharmaceutical industry.
Pharmaceutical companies continue to plan for the UK’s exit from the EU. As they do, the terms on which the UK will leave - and the terms of the future relationship – remain uncertain.
As Britain Brexits from the EU, it’s going to be more important than ever that the UK convincingly demonstrates to the world that it embraces new innovations.
With 10 million people a year projected to die from antibiotic-resistant infections by 2050, it’s important that all partners, including the pharmaceutical industry, step up and work together to tackle this issue.